6 / 15
Page 32
allied
academies
Journal of Pathology and Disease Biology | Volume 2
September 06-07, 2018 | Edinburgh, Scotland
Pathology and Surgical Pathology
International Conference on
RegenerAge System: Therapeutic effects of combinatorial biologics (mRNA and Allogenic MSCs) with a
Spinal cord stimulation system on a patient with Spinal Cord section
Joel I Osorio
RegenerAge Clinic, Mexico
A
s it has been previously demonstrated that co-
electroporation of Xenopus laevis frog oocytes with
normal cells and cancerous cell lines induces the expression
of pluripotency markers, and in experimental murine model
studies that mRNA extract (Bioquantine® purified from intra-
and extra-oocyte liquid phases of electroporated oocytes)
showed potential as a treatment for a wide range of conditions
as Squint, Spinal Cord Injury (SCI) and Cerebral Palsy among
others. The current study observed beneficial changes with
Bioquantine® administration in a patient with a severe SCI.
Pluripotent stem cells have therapeutic and regenerative
potential in clinical situations CNS disorders even cancer.
One method of reprogramming somatic cells into pluripotent
stem cells is to expose them to extracts prepared from Xenopus
laevis oocytes. We showed previously that coelectroporation of
Xenopus laevis frog oocytes; with normal cells and cancerous
cells lines, induces expression of markers of pluripotency.
We also observed therapeutic effects of treatment with a
purified extract (Bioquantine) of intra- and extra-oocyte liquid
phases derived from electroporated X. laevis oocytes, on
experimentally induced pathologies including murine models
of melanoma, traumatic brain injury, and experimental skin
wrinkling induced by squalene- monohydroperoxide (Paylian
et al, 2016). The positive human findings for Spinal Cord Injury,
and Cerebral Palsy with the results from previous animal
studies with experimental models of traumatic brain injury,
respectively (Paylian et al, 2016). Because of ethical reasons,
legal restrictions, and a limited number of patients, we were
able to treat only a very small number of patients. These
results indicate that Bioquantinemay be safe and well tolerated
for use in humans and deserves further study in a range of
degenerative disorders. We propose that the mechanism of
action of Bioquantine in these various diseases derives from
its unique pharmacology and combinatorial reprogramming
properties. In conclusion, these preliminary findings suggest
that Bioquantine is safe and well tolerated on patients with
Cerebral Palsy and Spinal Cord Injury, among others. In addition
to the regenerative therapy and due to the patient condition,
we decided to include the Restore-Sensor SureScan. Based on
the of electrical stimulation for rehabilitation and regeneration
after spinal cord injury published by Hamid and MacEwan,
we designed an improved delivery method for the in-situ
application of MSCs and Bioquantine in combination with the
RestoreSensor SureScan Conclusions: To the present day the
patient who suffered a total section of spinal cord at T12-L1
shows an improvement in sensitivity, strength in striated muscle
and smooth muscle connection, 11 months after the first
therapy of cell regeneration and 3 month after the placement
of RestoreSensor at the level of the lesion, the patient with a
complete medullary section shows an evident improvement on
his therapy of physical rehabilitation on crawling from front to
back by himself and standing on his feet for the first time and
showing a progressively important functionality on the gluteal
and legs sensitivity.
e:
drosorio@regenerage.clinic